ClinicalTrials.gg
TerminatedNCT06295809INTerpath-007Updated May 8, 2026

A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

A Phase 2/3 interventional study of Pembrolizumab and Intismeran autogene in Carcinoma, Squamous Cell and Skin Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated at 106 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 330 studies in Carcinoma, Squamous Cell with a site in United States — 68 open to participants now, 99 under way, 6 of them phase 3. Carcinoma, Squamous Cell · United States.

Enrollment
118th of 280
46 · median 37
Started
2024
with 10 others
Phase 2/3
4 of 330
1 open now
Registered
279th of 330
by date

Among the 330 studies in Carcinoma, Squamous Cell with a site in United States, this one is the 118th largest by enrollment of the 280 interventional ones that give a count, is one of 11 that started in 2024, is one of 4 in phase 2/3, and was the 279th registered.

Carcinoma, Squamous Cell

629 studies on the registry are indexed under Carcinoma, Squamous Cell; 135 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

68 of the 330 studies in Carcinoma, Squamous Cell with a site in United States are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Carcinoma, Squamous Cell with a site in United States, or all of them as a file.
02

Study summary

This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms intismeran autogene plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of intismeran autogene in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that intismeran autogene plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to intismeran autogene plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrollment or study endpoints.

As of Amendment 04, enrollment was stopped and there will be no Phase 3 expansion.

03

Conditions studied

  • Carcinoma, Squamous Cell
  • Skin Neoplasms

Keywords

  • pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of resectable cSCC as the primary site of ( skin involvement from another primary cancer or from an unknown primary cancer is not permitted).
  • Has LA Stage II-IV (M0) cSCC without distant metastases.
  • cSCC must be amenable to surgery (resectable) with curative intent.
  • Has a formalin-fixed, paraffin-embedded (FFPE) tumor sample available or is able to provide one that is suitable for the Next-generation Sequencing (NGS) required for this study.
  • For males, agrees to be abstinent from penile-vaginal intercourse OR agrees to use a highly effective method while receiving radiation therapy (RT), and for ≥3 months after the last dose of study intervention
  • Is female and not pregnant/breastfeeding and at least one of the following applies during the study : is not a woman of (WOCBP), is a WOCBP and uses highly effective contraception (low user dependency method OR a user dependent hormonal method in combination with a barrier method) at least during use of intismeran autogene: 15 days, Pembrolizumab: 120 days, Adjuvant RT, if performed: 90 days after last exposure or is a WOCBP who is abstinent from heterosexual intercourse.
  • Has per 1.1 as assessed by the local site investigator/radiology.
  • Has a of >3 months per investigator assessment.
  • Has an (ECOG) performance status of 0 to 1 assessed within 14 days before randomization.
  • Has adequate organ function.
  • If surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
  • If there is a history of virus (HCV) infection, HCV viral load must be undetectable at screening
  • If (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)

Exclusion criteria

Exclusion Criteria:

  • Has any other histologic type of skin cancer other than invasive cSCC as well as mixed histology, eg, basal cell carcinoma that has not been definitively treated with surgery or radiation, Bowen's disease, Merkel cell carcinoma (MCC), or melanoma
  • Has distant disease (M1), visceral and/or distant nodal
  • Has received prior therapy with an anti-programmed cell death receptor 1 (), anti-programmed cell death receptor ligand 1 (anti-PD-L1), or anti-programmed cell death receptor ligand 2 (anti-PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte associated protein 4 (CTLA-4), OX-40, CD137)
  • Has received prior systemic anticancer therapy including agents for cSCC before randomization
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Has received a live or within 30 days before the first dose of study intervention
  • Has received transfusion of blood products (including or red blood cells) or administration of colony stimulating factors (including granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 2 weeks of the screening blood sample (including the NGS blood sample)
  • Has received prior treatment with another cancer vaccine
  • Has received prior radiotherapy to the index lesion (in-field lesion). Must have recovered from all radiation-related toxicities prior to randomization and not have had radiation pneumonitis
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior the first dose of study medication
  • Has a known additional that is progressing or has required active treatment within the past 2 years
  • History of chronic lymphocytic leukemia (CLL)
  • History of central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has severe (≥Grade 3) to either intismeran autogene or pembrolizumab and/or any of its
  • Has an active disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has concurrent active (defined as HBsAg positive and/or detectable HBV DNA) and virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection
  • Has had a myocardial infarction within 6 months of randomization
  • History of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Pembrolizumab plus Intismeran autogene with SOC

    Participants will receive intismeran autogene 1 mg intramuscular (IM) injection every 3 weeks (q3w) for up to 6 weeks and pembrolizumab 400 mg intravenous (IV) infusion every 6 weeks (q6w) up to 12 weeks as neoadjuvant therapy prior to surgery; followed by intismeran autogene 1 mg IM injection q3w up to 21 weeks.

    Biological: Pembrolizumab · Biological: Intismeran autogene · Procedure: Surgery

  • Active comparator
    Standard of Care (SOC)

    Participants will receive surgical resection as per local guidelines with/without adjuvant radiation therapy (RT) at investigator's discretion.

    Procedure: Surgery

  • Experimental
    Pembrolizumab with SOC

    Participants will receive pembrolizumab 400 mg IV infusion q6w up to 12 weeks as neoadjuvant therapy prior to surgery.

    Biological: Pembrolizumab · Procedure: Surgery

Interventions

  • BiologicalPembrolizumab

    IV Infusion

    Also known as: MK-3475, Keytruda®

  • IM injection

    Also known as: mRNA-4157, V940

  • ProcedureSurgery

    Local resection of cancerous lesions of the skin

06

What researchers measure

Primary outcomes

  1. Event Free Survival (EFS)

    EFS is defined as the time from randomization to any of the following events as assessed by the investigator: progression of disease that precludes surgery, or inability to undergo R0 or R1 surgical resection; disease recurrence (local, regional, or distant); new primary high-risk cSCC; death due to any cause. EFS will be presented.

    Time frame: Up to ~22 months

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the proportion of participants who have a complete response (CR) or partial response (PR). ORR will be presented.

    Time frame: Up to ~22 months

  2. Freedom from surgery (FFS) rate

    FFS rate is defined as the proportion of participants with clinical CR with no residual tumor on clinical exam and imaging with the confirmation of negative biopsy. FFS rate will be presented.

    Time frame: Up to ~22 months

  3. Pathologic complete response (pCR) rate

    pCR rate is defined as the proportion of participants who have complete absence of viable tumor in the surgical resection specimen. The pCR rate will be presented.

    Time frame: Up to ~22 months

  4. Major pathologic response (mPR) rate

    mPR rate is defined as the proportion of participants who have ≤10% of viable tumor cells in the surgical resection specimen. The mPR rate will be presented.

    Time frame: Up to ~22 months

  5. Disease-specific survival (DSS)

    DSS is defined as time from randomization to death due to progression of cancer under study. DSS will be presented.

    Time frame: Up to ~22 months

  6. Overall Survival (OS)

    OS is defined as the time from the date of randomization to death due to any cause. The OS will be reported for all participants.

    Time frame: Up to ~22 months

  7. Percentage of participants who experience an adverse event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to ~22 months

  8. Percentage of participants who discontinue study intervention due to AEs

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue intervention due to an AE will be reported.

    Time frame: Up to ~22 months

07

Study locations

106 sites
  • USC/Norris Comprehensive Cancer Center ( Site 1112)
    Los Angeles, California 90033, United States
  • Hoag Memorial Hospital Presbyterian ( Site 1122)
    Newport Beach, California 92663, United States
  • Stanford Cancer Center ( Site 1109)
    Palo Alto, California 94304, United States
  • University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 1103)
    Sacramento, California 95817, United States
  • Winship Cancer Institute, Emory University ( Site 1151)
    Atlanta, Georgia 30322, United States
  • University of Iowa-Holden Comprehensive Cancer Center ( Site 1118)
    Iowa City, Iowa 52242, United States
  • University of Kentucky Chandler Medical Center ( Site 1101)
    Lexington, Kentucky 40536, United States
  • Ochsner Clinic Foundation ( Site 1113)
    New Orleans, Louisiana 70121, United States
  • Massachusetts General Hospital ( Site 1162)
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute ( Site 1130)
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine-Internal Medicine/Oncology ( Site 1100)
    St Louis, Missouri 63110, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1125)
    Hackensack, New Jersey 07601, United States
  • Atlantic Health System Morristown Medical Center ( Site 1136)
    Morristown, New Jersey 07960, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1160)
    Mineola, New York 11501, United States
  • Laura and Isaac Perlmutter Cancer Center ( Site 1121)
    New York, New York 10016, United States
  • Providence Portland Medical Center ( Site 1102)
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center ( Site 1107)
    Pittsburgh, Pennsylvania 15232, United States
  • Avera Cancer Institute- Research ( Site 1161)
    Sioux Falls, South Dakota 57105, United States
  • University of Virginia Health System ( Site 1115)
    Charlottesville, Virginia 22908, United States
  • Inova Schar Cancer Institute ( Site 1108)
    Fairfax, Virginia 22031, United States
  • University Hospital and UW Health Clinics ( Site 1119)
    Madison, Wisconsin 53792, United States
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1213)
    Mar del Plata, Buenos Aires 7600, Argentina
  • Fundacion Estudios Clinicos-Oncology ( Site 1205)
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Sanatorio Finochietto ( Site 1202)
    Buenos Aires, C1187AAN, Argentina
  • Investigaciones Clinicas Moleculares (ICM) ( Site 1212)
    CABA, C1425BGH, Argentina
  • Hospital Italiano de Córdoba ( Site 1204)
    Córdoba, X5004BAL, Argentina
  • Melanoma Institute Australia-Clinical Trials Unit ( Site 3205)
    Wollstonecraft, New South Wales 2065, Australia
  • Sunshine Coast University Hospital-Medical Oncology ( Site 3212)
    Birtinya, Queensland 4575, Australia
  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
    Brisbane, Queensland 4029, Australia
  • Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 3207)
    Gold Coast, Queensland 4215, Australia
  • Gallipoli Medical Research Ltd-GMRF CTU ( Site 3206)
    Greenslopes, Queensland 4120, Australia
  • Austin Health ( Site 3209)
    Heidelberg, Victoria 3084, Australia
  • One Clinical Research ( Site 3211)
    Nedlands, Western Australia 6009, Australia
  • Cliniques universitaires Saint-Luc ( Site 1701)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • UZ Gent-Medical oncology ( Site 1702)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Clinica Amo - Rio Vermelho-INSTITUTO ETICA ( Site 1315)
    Salvador, Estado de Bahia 41950-640, Brazil
  • Hospital de Cancer de Londrina-Clinical Research Unit ( Site 1316)
    Londrina, Paraná 86015-520, Brazil
  • Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 1309)
    Passo Fundo, Rio Grande do Sul 99010-080, Brazil
  • Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 1300)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • ANIMI - Unidade de Tratamento Oncologico ( Site 1312)
    Lages, Santa Catarina 88501001, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • IPITEC ( Site 1313)
    São Paulo, São Paulo 01223-001, Brazil
  • Jewish General Hospital ( Site 1009)
    Montreal, Quebec H3T 1E2, Canada
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer
    Sherbrooke, Quebec J1H 5H4, Canada
  • James Lind Centro de Investigacion del Cancer ( Site 1411)
    Temuco, Araucania 4800827, Chile
  • CIDO SpA-Oncology ( Site 1405)
    Temuco, Araucania 4810218, Chile
  • FALP-UIDO ( Site 1401)
    Santiago, Region M. de Santiago 7500921, Chile
  • Clínica Alemana de Santiago-Gynecology and Obstetrics ( Site 1410)
    Santiago, Region M. de Santiago 7650568, Chile
  • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1501)
    Medellín, Antioquia 050030, Colombia
  • Oncologos del Occidente ( Site 1504)
    Pereira, Risaralda Department 660001, Colombia
  • Fundación Valle del Lili ( Site 1502)
    Cali, Valle del Cauca Department 760032, Colombia
  • Vseobecna fakultni nemocnice v Praze-Department of Dermatology ( Site 1800)
    Prague, Praha 2 12808, Czechia
  • CHU de Bordeaux Hop St ANDRE ( Site 1902)
    Bordeaux, Aquitaine 33075, France
  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1903)
    Marseille, Bouches-du-Rhone 13005, France
  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1904)
    Dijon, Bourgogne-Franche-Comté 21000, France
  • Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE ( Site 1908)
    Toulouse, Haute-Garonne 31059, France
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu-Onco-Dermatology ( Site 1910)
    Nantes, Loire-Atlantique 44093, France
  • Hopital Claude Huriez - CHU de Lille ( Site 1907)
    Lille, Nord 59037, France
  • centre hospitalier lyon sud ( Site 1901)
    Pierre-Bénite, Rhone 69310, France
  • Hôpital Saint-Louis ( Site 1906)
    Paris, 75475, France
  • Gustave Roussy ( Site 1909)
    Villejuif, Île-de-France Region 94800, France
  • NCT ( Site 2002)
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinikum Tuebingen-Hautklinik ( Site 2003)
    Tübingen, Baden-Wurttemberg 72076, Germany
  • klinikum rechts der isar der technischen universität münchen ( Site 2009)
    München, Bavaria 81675, Germany
  • Universitaetsklinikum Wuerzburg-Department of Dermatology ( Site 2001)
    Würzburg, Bavaria 97080, Germany
  • Klinikum Dortmund Klinikzentrum Mitte ( Site 2008)
    Dortmund, North Rhine-Westphalia 44137, Germany
  • Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 2005)
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitätsmedizin Johannes Gutenberg Universität Mainz ( Site 2007)
    Mainz, Rhineland-Palatinate 55131, Germany
  • Universitätsklinikum Schleswig-Holstein-Dermatology ( Site 2012)
    Lübeck, Schleswig-Holstein 23538, Germany
  • Pécsi Tudományegyetem Klinikai Központ-Bőr-, Nemikórtani és Onkodermatológiai Klinika ( Site 2100)
    Pécs, Baranya 7632, Hungary
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Közpo-Department of Dermatology and Allergol
    Szeged, Csongrád megye 6720, Hungary
  • Debreceni Egyetem Klinikai Kozpont-Bőrgyógyászati Klinika ( Site 2102)
    Debrecen, 4032, Hungary
  • Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz- Onkoradiologiai Osztaly ( Site 2110)
    Győr, 9024, Hungary
  • Emek Medical Center ( Site 2203)
    Afula, 1834111, Israel
  • Hadassah Medical Center ( Site 2201)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center ( Site 2202)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center ( Site 2200)
    Ramat Gan, 5265601, Israel
  • Instituto Tumori Giovanni Paolo II ( Site 2301)
    Bari, Apulia 70124, Italy
  • Ospedale San Martino-Oncologia Medica 2 ( Site 2303)
    Genoa, Liguria 16132, Italy
  • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 2304)
    Rozzano, Milano 20089, Italy
  • Azienda Ospedaliero Universitaria Senese ( Site 2302)
    Siena, Tuscany 53100, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII-UOC Oncologia ( Site 2305)
    Bergamo, 24127, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi
    Naples, 80131, Italy
  • Harbour Cancer & Wellness ( Site 3300)
    Auckland, 1023, New Zealand
  • Oslo universitetssykehus, Radiumhospitalet ( Site 2400)
    Oslo, 0379, Norway
  • Centrum Medyczne HCP ( Site 2505)
    Poznan, Greater Poland Voivodeship 61-485, Poland
  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2501)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-796, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2506)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch
    Kielce, Świętokrzyskie Voivodeship 25-734, Poland
  • Spitalul Universitar de Urgență Elias ( Site 2600)
    Bucharest, Bucharest 011461, Romania
  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala ( Site 2602)
    Florești, Cluj 407280, Romania
  • Centrul de Oncologie Sfantul Nectarie-Medical ( Site 2601)
    Craiova, Dolj 200542, Romania
  • Sigmedical Services SRL ( Site 2603)
    Suceava, 720214, Romania
  • Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 2804)
    Badalona, Barcelona 08916, Spain
  • HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
    Barcelona, Catalonia 08036, Spain
  • Centro Oncologico de Galicia ( Site 2806)
    A Coruña, Galicia 15009, Spain
  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2801)
    Madrid, Madrid, Comunidad de 28034, Spain
  • H.R.U Malaga - Hospital General ( Site 2805)
    Málaga, Malaga 29010, Spain
  • Hospital General Universitario de Valencia-oncology service ( Site 2802)
    Valencia, Valenciana, Comunitat 46014, Spain

Showing the first 100 of 106 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Mar 2026, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 6, 2024
StartActual
Apr 18, 2024
Primary completionActual
Mar 5, 2026
CompletionActual
Mar 5, 2026
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06295809
Collaborators
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Apr 18, 2024
Primary completion
Mar 5, 2026
Completion
Mar 5, 2026
Last update
May 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Intismeran autogene

Start the discussion